Article PDF first page preview

First page of Real-world insights: Balancing diagnostic benefits and oncological risks of ureteroscopic biopsy before radical nephroureterectomy for upper tract urothelial carcinoma

Purpose: The role of diagnostic ureteroscopy (URS) prior to radical nephroureterectomy (RNU) remains controversial due to concerns about an increased risk of intravesical recurrence. However, existing studies frequently exhibit two major confounders: lack of reporting on the use of mitomycin C instillation after RNU and not excluding patients with a history of bladder cancer. Methods: We retrospectively evaluated the proportion of RNU patients for whom the URS biopsy result before RNU was decisive for therapy. The impact of URS biopsy on intravesical recurrence (IVR), overall survival (OS), and cancer-specific survival (CSS) was evaluated using univariate and multivariable Cox regression analyses and Kaplan-Meier curves. Results: Between January 2005 and November 2022, 229 patients with upper tract urothelial carcinoma (UTUC) underwent RNU with single post-operative mitomycin C instillation at our department. After excluding those with a history of bladder cancer, 148 RNU patients were included in the final analysis (prior URS biopsy: 125 (84%), no URS biopsy: 23 (16%)). Before RNU, both urine cytology and CT were inconclusive in 37% of patients. URS biopsy confirmed UTUC in 73% of these cases. Univariate and multivariable Cox regression analyses revealed no significant differences in IVR, OS, or CSS between patients who underwent URS biopsy before RNU and those who did not. Conclusion: URS biopsy was essential for clinical decision-making in one-third of patients who underwent RNU. There were no oncologic disadvantages for patients who underwent URS biopsy prior to RNU, demonstrating its utility in clinical practice without compromising oncologic outcomes.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.